HK Stock Market Move | SISRAM MED (01696) fell more than 4%, the restructuring at the controlling shareholder level has been completed.

SISRAM MED (01696) fell more than 4%, as of the time of writing, it dropped 3.24% to HK$2.99, with a turnover of HK$3.42 million. On the news front, on April 22, SISRAM MED announced a proposal for restructuring at the shareholder level. According to the restructuring announcement, Shanghai Fosun Pharmaceutical's indirectly wholly-owned subsidiary Nengyue and Meizhong Mutual respectively signed agreements to transfer all company shareholding interests (approximately 71.42% of the company's total issued shares as of the announcement date) to another indirectly wholly-owned subsidiary of Shanghai Fosun Pharmaceutical, FPI. On April 22, 2026, the company's board of directors received a notice from Shanghai Fosun Pharmaceutical that, in accordance with their agreement terms, the restructuring has been completed. As of the announcement date, Shanghai Fosun Pharmaceutical's indirectly wholly-owned subsidiary FPI holds 334.5 million shares of the company, and Shanghai Fosun Pharmaceutical indirectly maintains its shareholding in the company unchanged.